Womens Cancer Research Gains National Recognition
St. Luke's Gynecologic Oncologist Dr. Israel Zighelboim Participates in Women's Cancer Research Trial that Gains National Recognition
Bethlehem, PA (6/13/2013) - A research study on cervical cancer published online April 10 in the peer-reviewed publication Gynecologic Oncology is receiving recognition as national oncology news by the American Society of Clinical Oncology. St. Luke's fellowship-trained and board-certified gynecologic oncologist Israel Zighelboim, MD, FACS, FACOG, co-authored this study.
About the Research Study
Locally advanced cervical cancer has been traditionally treated with radiotherapy. The chemotherapeutic and radio-sensitizing agent Cisplatin has been an integral part of the treatment plan since 1999. At that time, multiple clinical trials demonstrated improved survival associated with its use.
According to the study, laboratory screening for cervical tumor sensitivity to the chemotherapy drug Cisplatin could predict prognosis. Patients carrying “Cisplatin-resistant” tumors had significantly worse progression-free survival. According to Dr. Zighelboim, “This study opens the door to potential individualized selection of adjuvant chemotherapeutic radio-sensitizers for patients with advanced cervical cancer.”
Dr. Zighelboim and Dr. Nicholas Taylor, gynecologic oncologists at St. Luke's University Health Network, are active researchers with special interest in novel therapeutics, treatment outcomes and genetic susceptibility to gynecologic cancer. As part of the Gynecologic Oncology Group, they collaborate with other nationally recognized cancer experts and researchers in order to develop cutting-edge therapies for patients with gynecologic malignancies.
Director, Marketing & Public Relations
St. Luke's University Health Network